Login
Benitec Biopharma Inc. logo

Benitec Biopharma Inc.

benitec.com

What Do They Do?

Develops genetic medicines designed to silence disease-causing genes and replace them with functional genes for people with genetic diseases, including OPMD.

Who Are Their Customers?

Its product candidates are still in development, so it has not established sales or distribution operations. If products are approved, it plans to use strategic alliances and distribution agreements, and may sell directly in some markets.

How Are They Changing?

Since the FY2026 annual report
  • Nov 12, 2026 Changed fiscal year-end to December 31 The company will report a six-month transition period, then use calendar-year reporting.
  • Sep 18, 2026 Replaced Baker Tilly with Ernst & Young as auditor The audit committee dismissed Baker Tilly and appointed Ernst & Young for the fiscal year ending June 30, 2027.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support